Brokers Issue Forecasts for Supernus Pharmaceuticals Inc’s Q4 2018 Revenue (SUPN)

Brokers Issue Forecasts for Supernus Pharmaceuticals Inc’s Q4 2018 Revenue (SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Investment analysts at B. Riley decreased their Q4 2018 EPS estimates for Supernus Pharmaceuticals in a research note issued to investors on Monday, November 12th. B. Riley analyst D. Buck now anticipates that the specialty pharmaceutical company will earn $0.27 per share for the quarter, down from their prior estimate of $0.34. B. Riley currently has a “Buy” rating and a $65.00 price objective on the stock. B. Riley also issued estimates for Supernus Pharmaceuticals’ FY2019 earnings at $2.55 EPS and FY2020 earnings at $3.55 EPS.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million during the quarter, compared to analysts’ expectations of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The business’s revenue was up 28.1% on a year-over-year basis. During the same period last year, the business earned $0.29 earnings per share.

SUPN has been the subject of a number of other reports. Cantor Fitzgerald set a $56.00 price objective on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 4th. ValuEngine cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. Piper Jaffray Companies reissued a “hold” rating and set a $46.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, July 25th. BidaskClub cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 7th. Finally, Jefferies Financial Group lifted their price objective on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and an average price target of $56.00.

Shares of NASDAQ SUPN opened at $43.06 on Wednesday. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of 34.17 and a beta of 0.92. Supernus Pharmaceuticals has a 52-week low of $34.90 and a 52-week high of $61.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.82 and a quick ratio of 2.65.

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Supernus Pharmaceuticals by 4.1% in the third quarter. BlackRock Inc. now owns 8,003,001 shares of the specialty pharmaceutical company’s stock valued at $402,951,000 after buying an additional 312,332 shares during the last quarter. FMR LLC raised its holdings in shares of Supernus Pharmaceuticals by 151.9% in the third quarter. FMR LLC now owns 2,371,321 shares of the specialty pharmaceutical company’s stock valued at $119,396,000 after buying an additional 1,430,021 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Supernus Pharmaceuticals by 6.8% in the second quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock valued at $57,290,000 after buying an additional 61,100 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Supernus Pharmaceuticals by 191.3% in the second quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after buying an additional 580,990 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Supernus Pharmaceuticals by 21.6% in the second quarter. Janus Henderson Group PLC now owns 665,392 shares of the specialty pharmaceutical company’s stock valued at $39,824,000 after buying an additional 118,289 shares during the last quarter. 98.30% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

See Also: Hedge Funds – How They Work For Investors

Related posts

Leave a Comment